Understanding IHH: The Role of IL-18 in Autoimmune Diseases (G3549)

Target Name: IHH

NCBI ID: G3549

Content of Review Report on IHH Target / Biomarker

IHH

Understanding IHH: The Role of IL-18 in Autoimmune Diseases

IHH (Immunomodulatory Hyperresponsiveness) is a term that was first introduced by Dr. J. David Strom in the field of immunology. It refers to a state of hypersensitivity in the immune system, where the body's immune system reacts to an harmless substance with an exaggerated or unnecessary response.

One of the most well-known examples of IHH is the condition known as \"Igulinous Hypermobility Syndrome\" (IHMS), also known as \"IgA Nephropathy.\" This is a type of autoimmune disease that affects the kidneys and can cause progressive kidney damage. People with IHMS have very high levels of antibodies in their urine, which are specific to the glomeruli.

Another example of IHH is "dermatomyositis" (pityrias rashes), a type of autoimmune disorder that causes itchy, blistered skin on the face, arms, and legs.

While the exact cause of IHH is not well understood, it is thought to involve an overreaction by the immune system to a normally harmless substance in the body. This can lead to inflammation, damage to body tissues, and a range of symptoms.

One potential drug target for IHH is the protein known as IL-18 (Interleukin-18). IL-18 is a cytokine that is produced by T-cells in response to an infection or other stressor. It has been shown to play a role in the regulation of inflammation and autoimmune responses.

IL-18 has also been shown to be involved in the development of cancer, and has been linked to a number of diseases, including heart disease, diabetes, and neurodegenerative disorders.

Research has also shown that high levels of IL-18 can be associated with an increased risk of developing autoimmune diseases, including IHMS.

Despite these findings, more research is needed to fully understand the role of IL-18 in IHH and to develop effective treatments. Currently ongoing clinical trials are focused on evaluating the effectiveness of IL-18 in the treatment of IHMS and other autoimmune diseases, and To evaluate the safety and efficacy of IL-18 as an immunotherapy target.

In addition to its potential use as a drug target, IHH is also of interest as a biomarker for the diagnosis and monitoring of autoimmune diseases. By measuring the levels of IL-18 in the body, doctors may be able to determine the severity of an autoimmune reaction and guide treatment decisions.

Overall, IHH is a complex and multifaceted condition that is still the subject of ongoing research. While the exact cause remains a mystery, the study of IL-18 and its role in IHH is a promising direction for future research.

Protein Name: Indian Hedgehog Signaling Molecule

Functions: The C-terminal part of the indian hedgehog protein precursor displays an autoproteolysis and a cholesterol transferase activity (By similarity). Both activities result in the cleavage of the full-length protein into two parts followed by the covalent attachment of a cholesterol moiety to the C-terminal of the newly generated N-product (By similarity). Both activities occur in the reticulum endoplasmic (By similarity). Plays a role in hedgehog paracrine signaling (PubMed:24342078). Associated with the very-low-density lipoprotein (VLDL) particles to function as a circulating morphogen for endothelial cell integrity maintenance (PubMed:20839884)

The "IHH Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IHH comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets